Evidence map›Paper›PMID 39804046›Full record

ArticleAntimicrobial agents and chemotherapy2025

Ceftobiprole activity against multidrug-resistant

Helio S Sader, Jennifer I Smart, Rodrigo E Mendes, Mariana Castanheira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Helio S SaderJMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA.ORCID 0000-0001-7022-6644
Jennifer I SmartBasilea Pharmaceutica International Ltd, Allschwil, Switzerland.
Rodrigo E MendesJMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA.
Mariana CastanheiraJMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with

Indexed as

Anti-Bacterial AgentsCephalosporinsMethicillin-Resistant Staphylococcus aureusCommunity-Acquired InfectionsDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsStaphylococcal InfectionsStaphylococcus aureusUnited StatesAnti-Bacterial AgentsceftobiproleCephalosporinsbacteremiaceftarolineceftobiprolecephalosporinMRSApneumoniaskin and skin structure infection

Identifiers

PMID39804046
PMCPMC11823664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.